Ameriprise
ORIC icon

Ameriprise’s Oric Pharmaceuticals ORIC Stock Holding History

Ameriprise’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-38,864
Closed -$394K – 4155
2025
Q2 		$394K Buy
38,864
+2,706
+7% +$18.2K ﹤0.01% 3605
2025
Q1 		$202K Buy
+36,158
New +$316K ﹤0.01% 3795
2024
Q4 		– Sell
-11,109
Closed -$114K – 4139
2024
Q3 		$114K Buy
+11,109
New +$110K ﹤0.01% 3823
2020
Q3 		– Sell
-10,998
Closed -$371K – 3767
2020
Q2 		$371K Buy
+10,998
New +$351K ﹤0.01% 3296

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Ameriprise's ORIC Position: Q3 2025 in Review

Ameriprise sold out of Oric Pharmaceuticals (ORIC) in Q3 2025, closing a stake of 38,864 shares — an estimated $394K sold.

Ameriprise first reported a position in ORIC in Q2 2020 and held it in 4 quarters. The position peaked at $394K in Q2 2025. 152 funds tracked by Wall St. Rank hold ORIC as of Q3 2025.

  • Ameriprise reported no remaining Oric Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Ameriprise sold 38,864 Oric Pharmaceuticals shares in Q3 2025, an estimated $394K.
  • Ameriprise first reported a position in Oric Pharmaceuticals in Q2 2020 and held it in 4 quarters.
  • Ameriprise's Oric Pharmaceuticals position peaked at $394K in Q2 2025.
  • 152 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2025.

Based on Ameriprise's 13F filing for Q3 2025, filed 14 Nov 2025.